What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To compare the clinical effectiveness and safety of Hydroxyurea versus newer FDA-approved therapies in managing sickle cell disease.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Network meta-analysis shows L-glutamine and newer therapies reduce vaso-occlusive crises and improve quality of life in sickle cell disease.

To compare the clinical effectiveness and safety of Hydroxyurea versus newer FDA-approved therapies in managing sickle cell disease.
Conducted a systematic search across five databases to identify randomized controlled trials (RCTs) related to sickle cell disease treatments.
Screened studies using Covidence and analyzed data with the Netmeta package in R.
Generated forest plots and performed meta-analyses using Stata 18.0, assessing risk of bias with the RoB 2.0 tool.
Included 11 RCTs with 2,242 total participants: 1,242 in treatment groups and 1,000 in controls.
L-glutamine showed the greatest reduction in vaso-occlusive crises with an odds ratio of 0.59.
Hydroxyurea improved hemoglobin levels by 1.1 g/dL, while other therapies showed varied efficacy.
Quality of life significantly improved with L-glutamine and Crizanlizumab, and low risk of bias was noted across studies.

Chopra et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Network meta-analysis shows L-glutamine and newer therapies reduce vaso-occlusive crises and improve quality of life in sickle cell disease.